learningcurve2020
5 months ago
Faith and Big Al hatched a scheme to default on a loan thereby abandoning their THER common shareholders leaving them in the dark while zeroing out their stock holdings. Never forget.
>>Faith Zaslavsky appointed as CEO to succeed Jeff Ervin FRANKLIN, Tenn. , May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings , Inc. (Nasdaq: BACK) (βIMACβ) today announced leadership transitions to the board of directors and executive team. Faith Zaslavsky has been appointed chief executive officer,
81vette
9 months ago
bought and bids in AGMH ,golden cross,low float (22m) vol. increasing last 40 days,global expansion news today,now # 1 on my profiting ticker scanner with 4Xs ave buying vol., actual vol dropping to nada is scary,huge accumulation today is before price in coming days/weeks. i have been buying these safer ones lately, while trading futures
81vette
9 months ago
my profiting ticker scanner,(above ave buying vol) WDH,CPSH,UONEK ,(not above ave buy volume but chart awesome to pop)> JOB,SY (buy back started today),all of these are profiting no scam beauties, i always got your back bro!
PENNIEStoSTACKS
2 years ago
The Theralink® Test for Advanced Breast Cancer measures the abundance and activation of 32 clinically actionable biomarkers. The test reports which of the 32 biomarkers are highly expressed or activated and the FDA-approved therapeutics that target them. This test is a novel tool that broadens actionability and supports oncologists in selecting the most effective treatment plan for their cancer patients.
Recently, Theralink received a Medicare reimbursement rate determination as well as added to its evidence based clinical utility data via an observational registry study that demonstrated greater than 90% actionability and greater than 70% clinical utility for the test. The Theralink test may be deemed necessary to achieve a personalized and targeted approach to breast cancer treatment
Through its current and planned lab developed tests (LDTs), Theralink's technology hopes to target multiple areas of oncology and drug development. In addition to the Company's first test for advanced breast cancer, Theralink is actively working on a pan-tumor test for solid tumors across multiple tumor types such as ovarian, endometrial, head and neck, pancreatic, colorectal, lung, prostate, among others
https://finance.yahoo.com/news/theralink-signs-definitive-merger-agreement-134300977.html